MDD XR 25 Tablet contains Desvenlafaxine 25 mg, a selective serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of major depressive disorder (MDD). Desvenlafaxine acts by increasing the levels of serotonin and norepinephrine in the central nervous system, which are neurotransmitters involved in mood regulation. This extended-release formulation provides a sustained therapeutic effect, allowing for once-daily dosing and improved patient compliance. MDD XR 25 is prescribed to alleviate symptoms of depression such as persistent sadness, loss of interest, and impaired daily functioning. The tablet should be taken orally with or without food, preferably at the same time each day to maintain consistent plasma levels. Dosage adjustments may be necessary based on clinical response and tolerability, with careful monitoring for adverse effects including nausea, dizziness, insomnia, and increased blood pressure. Caution is advised in patients with a history of bipolar disorder, seizure disorders, or those taking monoamine oxidase inhibitors (MAOIs) due to the risk of serotonin syndrome. Abrupt discontinuation should be avoided to minimize withdrawal symptoms. MDD XR 25 should be used under medical supervision with regular follow-up to assess efficacy and safety.